Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | ESRRG | P62508 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5318145 | 0.83 | NSD2 (0.60) | NSD2ALDH1A1HPGDMLYCD | |
| SCHEMBL8160105 | 0.81 | HDAC4 (0.45) | NSD2DRD2ACACBHDAC1HDAC6 | |
| SCHEMBL15801078 | 0.80 | DRD2 (0.40) | NSD2DRD2ACACBHDAC1HDAC6 | |
| SCHEMBL21115241 | 0.80 | NSD2 (0.43) | NSD2DRD2ACACBHDAC1HDAC6 | |
| SCHEMBL5048072 | 0.80 | ALDH1A1 (0.53) | ACACBALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19543258 | 0.79 | ALDH1A1 (0.48) | NSD2DRD2ACACBHDAC1HDAC6 | |
| SCHEMBL11979741 | 0.78 | NAMPT (0.48) | NSD2DRD2ACACBMLYCD | |
| SCHEMBL3422014 | 0.77 | ALDH1A1 (0.37) | NSD2ACACBPYCR1ALDH1A1HPGD | |
| SCHEMBL7533635 | 0.77 | ALDH1A1 (0.55) | HDAC1HDAC6ALDH1A1HPGD | |
| SCHEMBL12694301 | 0.76 | DRD2 (0.44) | NSD2DRD2ACACBSMN1; SMN2MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2359862-B1 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | INTEZYNE TECHNOLOGIES INC (US) | 2013-07-24 | — | — | EP | claimed |
| US-8258190-B2 | Encapsulated contrast agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-04 | — | — | US | claimed |
| EP-2359862-A1 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | Intezyne Technologies Inc. (US) | 2011-08-24 | — | — | EP | claimed |
| EP-2073850-B1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES INC (US) | 2010-10-27 | — | — | EP | claimed |
| JP-2010526183-A | — | — | 2010-07-29 | — | — | JP | claimed |
| EP-2152320-A2 | ENCAPSULATED CONTRAST AGENTS | Intezyne Technologies Incorporated (US) | 2010-02-17 | — | — | EP | claimed |
| EP-1907444-B1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES INC (US) | 2009-08-19 | — | — | EP | claimed |
| EP-2073850-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | Intezyne Technologies Incorporated (US) | 2009-07-01 | — | — | EP | claimed |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-09 | — | — | US | claimed |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | claimed |
| WO-2008134734-A2 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | WO | claimed |
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | claimed |
| WO-2008134731-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | WO | claimed |
| WO-2008106657-A2 | ENCAPSULATED AMYLOID-BETA PEPTIDES | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-09-04 | — | — | WO | claimed |
| EP-1907444-A2 | POLYMERIC MICELLES FOR DRUG DELIVERY | Intezyne Technologies Incorporated (US) | 2008-04-09 | — | — | EP | claimed |
| US-20060240092-A1 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | INTEZYNE TECHNOLOGIES, INC. | 2006-10-26 | — | — | US | claimed |
| WO-2006107903-A2 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-10-12 | — | — | WO | claimed |
| EP-3000833-B1 | MICELLES COMPRISING A TRIBLOCK COPOLYMER AND A THERAPEUTIC AGENT | INTEZYNE TECH INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20060142506-A1 | Heterobifunctional poly(ethylene glycol) and uses thereof | INTEZYNE TECHNOLOGIES, INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006047419-A2 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142506-A1 | Heterobifunctional poly(ethylene glycol) and uses thereof | GNE, ALG1, EPHX2 | NSD2 4724/4885DRD2 4602/4885ACACB 2267/4885 |
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | IAPP, APP, TTR | NSD2 4788/4885DRD2 4552/4885ACACB 2065/4885 |
| US-20060240092-A1 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | ABCB1, TERT, ABCB4 | NSD2 3253/4885DRD2 4348/4885ACACB 1653/4885 |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | LIPA, LPXN, CD47 | NSD2 4091/4885DRD2 3822/4885ACACB 2759/4885 |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | CLTB, SLC1A5, CLTA | NSD2 2585/4885DRD2 871/4885ACACB 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.